Drug intelligence / Profile preview

SGN-15 + gemcitabine

Development stage: Discontinued
Lead developer: Skagen
Modality: Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

SGN-15 + gemcitabine is an experimental combination therapy investigated for the treatment of cancers, specifically in a terminated Phase II trial for ovarian cancer. SGN-15 is an **antibody-drug conjugate** composed of the monoclonal antibody cBR96, which targets the Lewis Y (Le^y^) antigen, conjugated to the cytotoxic agent doxorubicin. Gemcitabine is a nucleoside analog that inhibits DNA synthesis. The combination aimed to enhance anti-tumor activity by leveraging the targeted delivery of doxorubicin to Le^y^-expressing carcinoma cells (via SGN-15) and the broad cytotoxic effect of gemcitabine, a DNA synthesis inhibitor.

Other names: SGN-15 (cBR96-doxorubicin immunoconjugate)gemcitabine hydrochloride

Targets

LeY (Lewis Y antigen)DNA polymerase familyRNR (Ribonucleotide reductase)

Beyond the preview

Go deeper on SGN-15 + gemcitabine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SGN-15 + gemcitabine.

Explore the full profile